Get the Stockscreener App
5.73
4.66%
-0.28
After Hours:
5.75
0.02
+0.35%
Replimune Group Inc stock is traded at $5.73, with a volume of 1.33M.
It is down -4.66% in the last 24 hours and up +9.14% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$6.01
Open:
$6
24h Volume:
1.33M
Relative Volume:
0.16
Market Cap:
$447.26M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-1.8133
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
-9.48%
1M Performance:
+9.14%
6M Performance:
-52.68%
1Y Performance:
-44.80%
1-Day Range:
$5.70
$6.0015
1-Week Range:
$5.70
$6.3272
52-Week Range:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
5.73 | 467.55M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
REPL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, - GlobeNewswire
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial InadequateHagens Berman - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
Replimune Group, Inc. Class Action: Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - Morningstar
Replimune Group, Inc. (NASDAQ:REPL) Receives $6.50 Average Target Price from Brokerages - MarketBeat
What institutional flow reveals about Replimune Group Inc.July 2025 PreEarnings & Precise Swing Trade Entry Alerts - Newser
REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug ApprovalHagens Berman - PR Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
REPL LAWSUIT ALERT: The Gross Law Firm Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Barchart.com
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
Trexquant Investment LP Sells 42,056 Shares of Replimune Group, Inc. $REPL - MarketBeat
Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $6.50 - Defense World
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - PR Newswire
Replimune Group, Inc. Class Action: The Gross Law Firm - GlobeNewswire
Replimune Group, Inc. INVESTOR ALERT: Kirby McInerney LLP Notifies Replimune Group, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - GlobeNewswire Inc.
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - Newsfile
Replimune Group's (REPL) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - Louisiana First News
Replimune Group, Inc. (NASDAQ: REPL) Investor Alert: Deadline in Lawsuit on September 22, 2025 - openPR.com
Replimune Group, Inc. Investors: Please contact the Portnoy - GlobeNewswire
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline - ACCESS Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Business Wire
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - Morningstar
Replimune Group’s (REPL) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
Shareholders SueWallSt in New Class Action Against Replimune Group, Inc.Act Now - Nasdaq
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - Morningstar
Replimune Group, Inc. $REPL Shares Purchased by Parkman Healthcare Partners LLC - MarketBeat
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky Before September 22, 2025 to Join Class Action - ACCESS Newswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending - GlobeNewswire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Real time alert setup for Replimune Group Inc. performanceJuly 2025 Pullbacks & Low Volatility Stock Suggestions - Newser
Securities Fraud Class Action Filed Against Replimune Group, Inc. (REPL)Levi & Korsinsky Reminds Investors of September 22, 2025 - ACCESS Newswire
Assessing Legal and Market Risks in Replimune Group, Inc. (REPL) Amid Ongoing Class Action Lawsuits - AInvest
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - The Malaysian Reserve
Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - PR Newswire
How to contact the Daily Bulletin - FinancialContent
Will Replimune Group Inc. continue its uptrend2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - Newser
Securities Fraud and Shareholder Risk at Replimune Group (REPL): Assessing the Financial and Reputational Impact of Securities Litigation on Biotech Valuations - AInvest
Full technical analysis of Replimune Group Inc. stockJuly 2025 Review & Low Risk High Win Rate Stock Picks - Newser
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class Action – Contact Levi & Korsinsky - ACCESS Newswire
Replimune Group Schedules Crucial FDA Meeting for RP1 - TipRanks
The Gross Law Firm Announces the Filing of a Securities - GlobeNewswire
Replimune Group, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - FinancialContent
Silicon Valley - FinancialContent
September 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against REPL - PR Newswire
Replimune's Regulatory Setback and Legal Exposure: A Cautionary Tale for Biotech Investors - AInvest
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):